NACL Industries Limited Stocks

161.69Last Updated 30.04.2026

Issuer Rating

2/7
Performance

Poor

Risk

Moderate

Recommendation

Sell

Market Cap

₹ 326.00M

Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
161.69
Key Takeaways

Risk factor

Poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly overvalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

NACL Industries Limited manufactures and sells agrochemicals in India. The company offers a range of technical products, including myclobutanil, propiconazole, profenofos, tricyclazole, and pretilachlors; and formulations, such as insecticides, fungicides, herbicides, and plant growth regulators and nematicides, as well as pesticides and acaricides. It also provides toll manufacturing services for various multinational companies. The company also exports its products to approximately 30 countries worldwide. It markets and sells its products through a network of retail dealers. The company was formerly known as Nagarjuna Agrichem Limited and changed its name to NACL Industries Limited in September 2017. The company was incorporated in 1986 and is based in Hyderabad, India. NACL Industries Limited is a subsidiary of KLR Products Limited.

Company Valuation

Greatly overvalued
1/7

Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers. Specifically, the stock is overvalued on EV/EBITDA.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis
X-channel

Buy

Sell

0 more stocks